News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Jounce Therapeutics
NEWS
JOBS
IN THE PRESS
NEWS
Juno Therapeutics was acquired by Bristol-Myers Squibb in 2019.
Deals
Cambridge-Based Jounce Files for $75 Million IPO
December 30, 2016
·
2 min read
Business
Cambridge Startup Jounce Lands $2.5 Billion Deal With Biotech’s Best Friend Celgene
July 19, 2016
·
2 min read
Drug Development
EXCLUSIVE: Jounce CEO Says Funding Aims for Trials Next Year, Will Hire 10
April 24, 2015
·
3 min read
Genetown
Jounce Infused With $56 Million to Develop Cancer Immunotherapy Programs
April 23, 2015
·
2 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Genetown
Jounce Therapeutics to Present at Upcoming Investor Conferences in November
November 9, 2021
·
2 min read
Business
Jounce Therapeutics Reports Third Quarter 2021 Financial Results
November 4, 2021
·
12 min read
Business
Jounce Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021
October 28, 2021
·
1 min read
Genetown
Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors
October 7, 2021
·
8 min read
Business
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
September 15, 2021
·
6 min read
Genetown
Jounce Therapeutics to Present at Upcoming Investor Conferences in September 2021
September 2, 2021
·
2 min read
Business
Jounce Therapeutics Reports Second Quarter 2021 Financial Results
August 5, 2021
·
11 min read
Business
Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021
July 29, 2021
·
2 min read
Genetown
Jounce Therapeutics to Participate in William Blair’s Biotech Focus Conference
July 7, 2021
·
1 min read
Genetown
Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day
June 23, 2021
·
7 min read
